Depression in alpha-synucleinopathies: prevalence, pathophysiology and treatment.
Parkinson's disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy (MSA) are increasingly recognized as alpha-synucleinopathies, i.e. neurodegenerative disorders that share a common subcellular pathology characterized by alpha-synuclein abnormal aggregation. In the present review we focus on depression in alpha-synucleinopathies, discussing epidemiological, pathophysiological and treatment aspects of this frequently disabling clinical feature which may occur in PD, DLB and MSA alike.
Stefanova
N
N
Department of Neurology, University Hospital, Innsbruck, Austria.
Seppi
K
K
Scherfler
C
C
Puschban
Z
Z
Wenning
G K
GK
D000818:Animals; D000928:Antidepressive Agents / Q000627:therapeutic use; D001921:Brain / Q000503:physiopathology; D003866:Depressive Disorder / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology; D003937:Diagnosis, Differential; D006801:Humans; D020961:Lewy Body Disease / Q000523:psychology*; D019578:Multiple System Atrophy / Q000523:psychology*; D009419:Nerve Tissue Proteins / Q000378:metabolism*; D010300:Parkinson Disease / Q000523:psychology*; D015995:Prevalence; D051843:Synucleins; D051844:alpha-Synuclein
D000928:Antidepressive Agents; D009419:Nerve Tissue Proteins; C497604:SNCA protein, human; D051843:Synucleins; D051844:alpha-Synuclein